Jason Murata is a partner in the intellectual property litigation group and chair of Axinn's Diversity, Equity & Inclusion Committee. Jason's practice involves all aspects of pre-trial, trial and appeals, with a particular focus on the pharmaceutical and biopharmaceutical, technology, consumer products, and food industries. He also brings extensive litigation experience to bear on complex issues relating to managing a company's IP risks and freedom to operate.

Professional Activities

• American Intellectual Property Law Association, Committee on the Profession
• American Bar Association, Section of Intellectual Property Law

Experience

• Mayne Pharma Int’l Pty Ltd. v. Merck & Co., Inc., No. 15-cv-00438 (D. Del.) (patent infringement action relating to Merck’s Noxafil posaconazole products)

• Globus Medical, Inc. v. DePuy Synthes Products, LLC, No. 13-cv-00854 (D. Del.) (defend patent infringement action relating to spinal fusion implants)

• Otsuka Pharmaceutical Co., Ltd. v. Zydus Pharmaceuticals USA Inc., Nos. 14-cv-03158-JBS-KMW & 14-cv-07252-JBS-KMW (D.N.J.) (obtained denial of motion for temporary restraining order in patent infringement action relating to generic aripiprazole drug product (Abilify))

• Pfizer, Inc. v. Tiger Pharmaceuticals, LLC, No. 14-cv-01501-AJT-TRJ (E.D. Va.); Pfizer, Inc. v. Tiger Pharmaceuticals, LLC, No. 14-cv-08958-GHW (S.D.N.Y.); Johnson Matthey Inc. v. Pfizer, Inc., 2:15-cv-00014-AWA-TEM (E.D. Va.) (obtained dismissal of patent infringement action relating to dofetilide drug product within four months of filing of the action)

• Depomed, Inc. v. Actavis Elizabeth LLC, No. 3:12-cv-01358 (D.N.J.) and Appeal No. 14-1828 (Fed. Cir.) (bench trial in patent infringement action relating to generic once-daily gabapentin product)

• The Procter & Gamble Co. v. Conopco, Inc., No. 13-CV-00732-TSB (S.D. Ohio) (represented Unilever in patent infringement action relating to antidandruff shampoo products)

• Brandeis University v. Unilever United States, Inc., No. 12-cv-01510 (N.D. Ill.) (Posner, J.) (represented Unilever in patent infringement action brought by marketer of SmartBalance products relating to margarines and buttery spreads)

• Hospira, Inc. v. Sun Pharmaceutical Industries, Inc., No. 2:10-cv-14514 (BAF/MJH) (E.D. Mich.) (defense of patent infringement action relating to generic dexemdetomidine drug product)

• Tyco Healthcare Group LP, et al. v Mutual Pharmaceutical Co., Inc., et al., Civil Action No. 07-cv-1299 (D.N.J.) and Appeal No. 2010-1513 (Fed. Cir.) (obtained summary judgment of invalidity that asserted patent was obvious, which was affirmed by Federal Circuit)
• In re Gabapentin Patent Litigation, MDL No. 1384, Master Civil Action No. 00-2931 (D.N.J.) (patent infringement dispute involving gabapentin)
• Aventis Pharmaceuticals Inc., et al. v. Sun Pharma Global Inc., et al., Civil Action Nos.  09-cv-00325 & -05179; Civil Action No.: 2:09-cv-5179-JAG (D.N.J.) (patent infringement dispute involving fexofenadine and fexofenadine / pseudoephedrine products)
• Roche Palo Alto LLC. v. Endo Pharmaceuticals Inc., Civil Action No. 10-cv-00261-GMS (D. Del.) (patent infringement dispute involving valganciclovir hydrochloride)
• United States Gypsum Co. v. Lafarge North America, Inc., Lafarge S.A., et al., Civil Action No. 03-CV-6027 (N.D. Ill. 2003) (theft of confidential, proprietary and trade secret information and patent infringement involving gypsum drywall manufacturing)
• Pall Corp. v. Entegris, Inc., Civil Action No. 07-CV-1869 (E.D.N.Y. 2007) (infringement dispute concerning filter media packing and capsule design)
•  Pall Corp. v. Entegris, Inc., Civil Action No. 05-CV-5894 (E.D.N.Y. 2005) (patent infringement dispute involving filter assembly methods and pre-wet packaging)
• Entegris, Inc. v. Pall Corp., Appeal Nos. 2004-1440, 2005-1265, -1266, 2006-1374 (Fed. Cir. 2006) (appeal from preliminary injunction and contempt order in patent infringement dispute concerning filter assembly)
• AstraZeneca AB, et al. v. Mutual Pharmaceutical Co., Inc., Appeal No. 04-1100 (Fed. Cir. 2004) (appeal in pharmaceutical case relating to generic extended-release felodipine tablets)
• Ciba Specialty Chemicals Corp. v. Zinkan Enterprises Inc., et al., Civil Action No. C2 03 174 (S.D. Ohio 2002) (patent infringement dispute involving treatment of wastewater from coal mining) 

Honors

• Profiles in Diversity Journal Asian Leadership Award Winner (2023)
• New Leaders in the Law – Connecticut Law Tribune (2014) 

News

• Jason Murata Named a Profiles in Diversity Journal Asian Leadership Award Winner
• Axinn’s Client Awarded Attorneys’ Fees in “Exceptional” PIV Case
• Axinn Named a "Legal Lion" for Federal Circuit Patent Win
• Axinn Launches California Office, Bringing Elite Antitrust and IP Practices to West Coast
• Axinn Promotes Jeny Maier and Jason Murata
• Federal Circuit Rules for Axinn Client in Abilify Patent Appeal
• Axinn Successfully Argues for Claim Construction in Mayne v. Merck
• Axinn Obtains Stipulated Summary Judgment of Non-Infringement for Zydus
• Axinn Successfully Obtains Dismissal for Zydus Pharmaceuticals
• Axinn Obtains Denial of a TRO Motion for Client Zydus
• Jason Murata Selected as New Leader in the Law
• Axinn Promotes Attorneys Steinthal and Murata
• Axinn Wins Summary Judgment on Behalf of Mutual Pharmaceutical Company
• View More ›

Thought Leadership

• American Intellectual Property Law Association Featured Member, March 31, 2022
• Queer IP Attys Say It's Time to Break Down the L, G, B & T, Law360, December 7, 2021
• When Japanese Witnesses Testify in U.S. Courts: Answers to Nine Common Concerns, January 2021
• The 2020 Axinn Survey of U.S. Litigation Involving Japanese Companies, November 2020
• Inclusion Matters, Now More Than Ever: Practical Suggestions for Making a Difference, AIPLA Innovate Magazine, July 10, 2020
• Attorney-Client Privilege in the United States: Recent Trends in its Application to Japanese Patent Professionals, AIPPI Journal, April 2020
• The 2019 Axinn Survey of U.S. Litigation Involving Japanese Companies, March 2020
• Axinn Insights on U.S. Litigation for Japanese Companies: The Duty to Preserve Documents and Implement Litigation Holds in U.S. Civil Litigation, August 19, 2019
• 23andMe to Appeal to Federal Circuit in Spat With Ancestry.com, BioWorld MedTech, November 12, 2018
• Integrating Trade Secrets into a Comprehensive IP Strategy, Today's General Counsel, June 19, 2018
• How Much Detail Should You Provide in a Patent Infringement Complaint?, Intellectual Property Magazine, December 2016
• Recent Developments in Japanese and U.S. Trade Secret Laws, Business Law Journal, No. 104, November 2016
• How a Merck Attorney’s Lies Torpedoed a $200M Patent Verdict, Law360 In-Depth, June 13, 2016
• The Next AIA Battleground: IPR And Estoppel, Law360, May 26, 2016
• Twombly, Iqbal And The Demise Of Form 18, Law360, November 18, 2014
• Are Your Secrets Safe?, Risk Management, June 1, 2014
• Protecting Business Trade Secrets When Working Abroad, Hartford Business Journal, April 28, 2014
• IP Law: Trade Secrets And Patent Reform, The Connecticut Law Tribune, April 17, 2014
• Obviousness in Medical Device Patent Litigation, Corporate Counsel, September 16, 2013

Events

Education

• JD – Washington University School of Law (2002)
• MA, Biology – Washington University (2002)
• BS, Biochemistry – McMaster University (1999)

Admissions

• California
• Connecticut
• Illinois
• New York
• US Court of Appeals for the Federal Circuit
• US District Court Northern District of Illinois
• US District Court Northern District of California